Strategically De-Risking U.S. Drug Supply Chains
As global trade tensions escalate, the United States may benefit from applying the concept of precision medicine to strengthen domestic resiliency in the biopharmaceutical industry. This could entail de-risking—without fully severing—drug supply chains with China.